Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Current Value
$88.111 Year Return
Current Value
$88.111 Year Return
Market Cap
$109.36B
P/E Ratio
989.29
1Y Stock Return
17.49%
1Y Revenue Growth
3.72%
Dividend Yield
3.70%
Price to Book
5.9
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ADM | 41.13% | $25.34B | -28.13% | 2.82% |
DOX | 37.57% | $9.47B | -0.74% | 2.26% |
JNJ | 36.41% | $368.37B | +1.24% | 3.18% |
INCY | 35.03% | $13.59B | +32.56% | 0.00% |
VTRS | 33.71% | $15.58B | +39.13% | 3.70% |
CTSH | 33.66% | $37.84B | +8.64% | 1.95% |
TGNA | 32.80% | $2.88B | +12.74% | 2.67% |
BMY | 31.79% | $118.10B | +20.11% | 4.09% |
PETS | 30.52% | $93.60M | -41.21% | 0.00% |
ABT | 30.33% | $203.16B | +14.93% | 1.88% |
DGX | 29.59% | $17.99B | +19.98% | 1.84% |
ABBV | 29.40% | $294.35B | +20.07% | 3.72% |
ACRE | 29.22% | $388.89M | -28.20% | 15.31% |
LH | 29.08% | $19.76B | +11.24% | 0.91% |
ESNT | 29.05% | $5.93B | +16.81% | 1.96% |
CSGS | 28.50% | $1.58B | +5.75% | 2.18% |
ELS | 28.21% | $13.54B | +2.00% | 2.66% |
BIIB | 28.05% | $22.65B | -32.30% | 0.00% |
BNL | 27.96% | $3.21B | +9.29% | 6.76% |
HTZ | 27.92% | $568.49M | -52.77% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FARM | 0.01% | $41.47M | -25.00% | 0.00% |
PRPL | -0.02% | $91.37M | +7.08% | 0.00% |
ITRN | -0.02% | $569.91M | +10.76% | 5.16% |
CSL | -0.02% | $19.72B | +59.12% | 0.85% |
KRP | 0.03% | $1.29B | +2.58% | 11.03% |
ARHS | 0.03% | $1.30B | +6.48% | 0.00% |
NRG | 0.03% | $19.22B | +109.87% | 1.71% |
S | 0.05% | $8.76B | +59.38% | 0.00% |
AG | 0.05% | $2.01B | +21.76% | 0.28% |
CCOI | -0.07% | $3.92B | +20.28% | 4.84% |
BAH | -0.08% | $17.62B | +9.13% | 1.47% |
FF | 0.09% | $227.57M | +21.57% | 4.55% |
CLMT | -0.10% | $1.79B | +35.14% | 0.00% |
BROS | 0.10% | $5.67B | +74.77% | 0.00% |
UTI | -0.11% | $1.07B | +73.54% | 0.00% |
SPOK | 0.12% | $323.34M | -6.07% | 7.89% |
PAYS | -0.13% | $176.71M | +37.50% | 0.00% |
FPI | 0.13% | $600.71M | +2.46% | 1.94% |
RCL | -0.13% | $63.10B | +123.86% | 0.17% |
KRRO | -0.14% | $436.84M | +20.68% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CMG | -20.77% | $80.02B | +33.62% | 0.00% |
NVDA | -20.46% | $3.61T | +194.35% | 0.07% |
VRT | -20.37% | $52.90B | +230.61% | 0.07% |
MELI | -19.47% | $97.16B | +28.15% | 0.00% |
VECO | -17.88% | $1.48B | -9.94% | 0.00% |
ONTO | -17.65% | $8.04B | +20.50% | 0.00% |
TT | -17.37% | $92.94B | +82.73% | 0.79% |
CAMT | -17.08% | $3.40B | +16.39% | 0.00% |
CLS | -16.69% | $10.10B | +223.71% | 0.00% |
MOD | -15.91% | $7.14B | +163.53% | 0.00% |
WDC | -15.88% | $22.57B | +41.20% | 0.00% |
MAGN | -14.95% | $638.97M | -3.42% | 0.00% |
AMAT | -14.61% | $139.58B | +13.44% | 0.85% |
ANF | -14.54% | $7.28B | +92.60% | 0.00% |
EME | -14.51% | $23.65B | +140.34% | 0.18% |
SNPS | -14.47% | $82.03B | -1.18% | 0.00% |
PSTG | -14.15% | $16.35B | +36.41% | 0.00% |
FIX | -14.00% | $16.89B | +145.93% | 0.25% |
CEPU | -13.85% | $2.07B | +87.28% | 0.00% |
ASML | -13.84% | $260.51B | -3.25% | 1.03% |
SeekingAlpha
Autolus Therapeutics' AUCATZYL shows strong potential despite safety concerns. Find out why AUTL stock is a Buy.
MarketWatch
Gilead Sciences Inc. stock outperforms competitors on strong trading day
SeekingAlpha
Gilead Sciences, Inc. (NASDAQ:GILD) 2024 Jefferies London Healthcare Conference November 20, 2024 4:30 AM ETCompany ParticipantsDan OâDay - Chairman and...
SeekingAlpha
Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.
SeekingAlpha
Investment activity in October focused on Business Development Companies. Check out my portfolio, my main picks, and my target for 2024.
SeekingAlpha
The fund posted a return of 9.08% (Class I shares) for the third quarter of 2024. Read more here.
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLTR | -0.11% | $1.79B | 0.14% |
FXL | 0.14% | $1.39B | 0.62% |
AMDY | 0.16% | $144.24M | 0.99% |
EWJV | 0.18% | $258.12M | 0.15% |
IVOL | -0.26% | $548.70M | 1.02% |
URNJ | 0.30% | $283.55M | 0.8% |
PIZ | 0.30% | $166.31M | 0.8% |
DUSB | -0.33% | $797.63M | 0.15% |
IOO | -0.36% | $6.28B | 0.4% |
BILZ | 0.39% | $563.02M | 0.14% |
GSY | -0.42% | $2.29B | 0.23% |
SNSR | 0.48% | $233.01M | 0.68% |
RSPT | -0.49% | $3.51B | 0.4% |
CGGO | -0.49% | $4.67B | 0.47% |
TAIL | -0.59% | $67.98M | 0.59% |
HACK | 0.66% | $1.80B | 0.6% |
SEIX | 0.81% | $268.81M | 0.62% |
UUP | -0.88% | $309.25M | 0.77% |
IBMM | -0.90% | $391.28M | 0.18% |
URNM | 0.97% | $1.61B | 0.75% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 41.79% | $397.87M | 0.35% |
IBB | 39.50% | $6.66B | 0.45% |
FBT | 35.19% | $1.11B | 0.56% |
FTXG | 35.14% | $30.81M | 0.6% |
HDV | 34.96% | $11.19B | 0.08% |
SPHD | 34.40% | $3.46B | 0.3% |
FXH | 34.21% | $1.15B | 0.62% |
LVHD | 33.97% | $560.70M | 0.27% |
RSPH | 33.78% | $885.96M | 0.4% |
FHLC | 33.38% | $2.73B | 0.084% |
VHT | 33.07% | $17.06B | 0.1% |
SPLV | 33.00% | $8.93B | 0.25% |
XLV | 32.56% | $38.41B | 0.09% |
SDOG | 32.06% | $1.24B | 0.36% |
FXG | 31.91% | $393.25M | 0.63% |
FDL | 31.88% | $4.50B | 0.45% |
FVD | 31.82% | $9.70B | 0.6% |
IYH | 31.38% | $3.19B | 0.39% |
SCHD | 31.36% | $65.70B | 0.06% |
IYK | 30.99% | $1.30B | 0.4% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBA | -17.52% | $755.88M | 0.93% |
EQLS | -15.50% | $76.08M | 1% |
ARGT | -13.26% | $571.58M | 0.59% |
SMH | -12.12% | $23.66B | 0.35% |
VCAR | -11.72% | $9.00M | 1.2% |
IBTE | -11.30% | $1.70B | 0.07% |
MTUM | -11.03% | $13.13B | 0.15% |
GCC | -10.47% | $133.23M | 0.55% |
FTGC | -10.40% | $2.17B | 1.02% |
KRBN | -10.38% | $242.47M | 0.85% |
PDBC | -10.37% | $4.40B | 0.59% |
DBC | -10.30% | $1.39B | 0.87% |
FFTY | -10.04% | $67.59M | 0.8% |
FTEC | -9.86% | $12.59B | 0.084% |
IGM | -9.85% | $5.60B | 0.41% |
VGT | -9.76% | $80.62B | 0.1% |
QGRW | -9.70% | $584.66M | 0.28% |
PSI | -9.43% | $711.93M | 0.56% |
EWN | -9.14% | $252.22M | 0.5% |
GSG | -8.95% | $914.42M | 0.75% |